Pioglitazone
Specifications
111025-46-8CAS Number
601-029-7EC Number
5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dioneIUPAC Name
C19H20N2O3SChemical Formula
356.4 g/molMolecular Weight
Pioglitazone; 111025-46-8; Glustin; Zactos; Pioglitazona; Pioglitazonum; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; AD-4833; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; CHEBI:8228; X4OV71U42S; U-72107; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; DTXSID3037129; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; U72,107A; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-1,3-thiazolidine-2,4-dione; 5-((4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)methyl)-1,3-thiazolidine-2,4-dione; RefChem:56525; DTXCID1017129; A10BG03; AD4833; U72107A; 601-029-7; 921-004-7; Actos; 105355-27-9; Pioglitazonum [INN-Latin]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; Pioglitazona [INN-Spanish]; U 72107; MFCD00865504; 105390-47-4; C19H20N2O3S; pioglitazone (INN); Pioglitazone (Actos); Actos (TN); 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; PIOGLITAZONE [INN]; Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Piozone; Pioglu; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-; HSDB 7322; U-72107E; UNII-X4OV71U42S; Pioglitazone?; SR-01000763737; Pioglitazone base; 5-(4-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; [( inverted exclamation markA)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; 2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-, (+/-)-; Pioglitazone-[d4]; HS-0047; Spectrum_001623; Pioglitazone (Standard); Spectrum2_001679; Spectrum3_001002; Spectrum4_001130; Spectrum5_001480; Spectrum5_002067; PIOGLITAZONE [MI]; PIOGLITAZONE [HSDB]; PIOGLITAZONE [IARC]; SCHEMBL4121; PIOGLITAZONE [VANDF]; Pioglitazone (U-72107); BSPBio_002723; KBioGR_001619; KBioSS_002103; MLS006011848; PIOGLITAZONE [WHO-DD]; SPBio_001897; GTPL2694; orb1226974; orb1310828; PIOGLITAZONE [EMA EPAR]; SCHEMBL29364546; KBio2_002103; KBio2_004671; KBio2_007239; KBio3_001943; Pioglitazone - Bio-X trade mark; HYAFETHFCAUJAY-UHFFFAOYSA-N; BDBM724000; GLXC-05211; HMS2089H14; HMS3651D09; HMS3712E16; HMS3884L10; HMS5081P07; Pharmakon1600-01504401; MSK11071; BDBM50103521; EBC-14016; HB4139; HY-13956R; NSC758876; s2590; STL309607; STL373406; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; AKOS015894953; AKOS022109420; AC-1021; CCG-220107; CS-1700; DB01132; FP39372; SB17323; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; NCGC00163128-01; NCGC00163128-02; NCGC00163128-03; NCGC00163128-04; NCGC00163128-05; NCGC00163128-06; NCGC00163128-07; NCGC00163128-24; BP164273; HY-13956; SMR002204015; SY017473; SBI-0206791.P001; US20250064791, Compound Pioglitazone; DB-027350; NS00000599; SW197561-3; C07675; D08378; EN300-117258; AB00698454-10; AB00698454_11; AB00698454_12; AB00698454_13; F386732; Q417765; SR-01000763737-5; BRD-A48430263-001-07-7; BRD-A48430263-003-02-4; BRD-A48430263-003-06-5; BRD-A48430263-003-16-4; BRD-A48430263-003-17-2; Z1501480426; 5-[4-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(5-ethyl-2-pyridyl)eth-oxy]benzyl]-2,4-thiazolidinedione; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-(P-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE; (RS)-5-(4-(2-(5-ETHYLPYRIDIN-2-YL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-4-hydroxy-1,3-thiazol-2(5H)-one; [()-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; 198077-89-3Synonyms
Products Containing Pioglitazone
COMPETACT 15 mg/850 mg COMPRIMIDOS RECUBIERTOS CON PELICULAACTOS 30 mg COMPRIMIDOSACTOS 30 MG COMPRIMIDOSACTOS 30 MG COMPRIMIDOSACTOS 30 MG COMPRIMIDOSACTOS 30 MG COMPRIMIDOSTANDEMACT 30 mg/4 mg COMPRIMIDOSTANDEMACT 30 mg/2 mg COMPRIMIDOSPIOGLITAZONA ACCORD 15 MG COMPRIMIDOS EFGCOMPETACT 15 mg/850 mg COMPRIMIDOS RECUBIERTOS CON PELICULAACTOS 30 mg COMPRIMIDOSACTOS 30 mg COMPRIMIDOS
Page 1 of 3
Companies Selling Pioglitazone
CH
Cadila Healthcare (India)IndiaJH
JIANGSU HANSYN PHARMACEUTICAL CO., LTDChinaAH
Accord Healthcare S.L.U.SpainCT
Công ty TNHH TM Quốc tế ấn việtViet NamTP
Takeda Pharma A/SSpain